RadSep’s Purification and Molecular Recognition Technology
February 19, 2026
RadSep, Inc., a subsidiary of IBC Advanced Technologies, Inc., provides state-of-the-art purification technology and novel chelators for medical radioisotopes and their precursors (Ac-225, Ra-224, Ra-225, Ra-226, Ra-228, Th-228, Th-232, Pb-212, Cu-67, and more).
RadSep offers Molecular Recognition Technology™ (MRT™) resins that are extremely selective, stable and simple to use. First-pass recoveries and purities of 99.9+% are achieved due to the high selectivity and capacity of MRT™ resins. In addition, their high radiolytic stability enables reuse for multiple separation cycles. MRT™ separation systems deliver maximum useable activity while minimizing manufacturing space and waste. Thus, MRT™ makes radioisotope production compatible with radiopharmaceutical manufacturing at scale.
As an award-winning manufacturer, RadSep also offers highly selective chelators for various radioisotopes.
Learn more at https://radsep.com
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
